Clinical trials: Co-Infection HIV-HCV
HIV, Hepatitis C
Safety Study of Raltegravir in HIV/HCV Co-infected Patients
Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection recommend a combination antiretroviral regimen composed of two nucleoside reverse transcriptase inhibitors plus a ritonavir boosted…
- Trial name
- NCT01225705
- Testing
- raltegravir, Atazanavir/ritonavir
- Where
- 8 sites in Germany
- Sponsor
- University Hospital, Bonn
Hepatitis C, HIV
HCV Treatment in HIV Co-Infected Patients in Asia
The purpose of this study is to assess the effectiveness and tolerability of hepatitis C virus (HCV) treatment in HIV co-infected patients in routine health care services in Asia through a pilot model of care for treatment of HCV…
- Trial name
- NCT01838772
- Testing
- Pegylated-Interferon and Ribavirin
- Where
- 4 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 188 people
- Sponsor
- amfAR, The Foundation for AIDS Research
Hepatitis C Infection, HIV Infection
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Background: Chronic hepatitis C (CHC) is a major health problem that particularly affects individuals with human immunodeficiency virus (HIV) infection, and can lead to cirrhosis and liver failure.
- Trial name
- NCT01185028
- Testing
- Nitazoxanide With Pegylated Interferon And Ribavirin
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV, Hepatitis C
THISTLE - The HIV-HCV Silibinin Trial
Chronic hepatitis C virus (HCV) is a major cause of morbidity and mortality worldwide with an estimated number of 180 million infected patients.
- Trial name
- THISTLE (NCT01816490)
- Testing
- Intravenous Silibinin (iSIL)
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Chronic Hepatitis C, Human Immunodeficiency Virus
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.
- Trial name
- NCT01783678
- Testing
- Sofosbuvir, RBV
- Where
- 24 sites in Australia, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
HIV, Hepatitis C
Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons
Two types of brief intervention, Brief Advice (BA) and Motivational Interviewing (MI), have been shown to be efficacious in reducing drinking in non-HIV samples.
- Trial name
- REACH (NCT02316184)
- Testing
- Motivational Interviewing, Brief Advice
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Butler Hospital
HCV-HIV Co-Infection
Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders
Evaluation of efficacy and tolerance to a QUadruple therapy with Asunaprevir , Daclatasvir, Ribavirin and pegylated Interferon alpha-2a, in HIV-HCV genotype 1 or 4 coinfected patients previously null responders to a standard…
- Trial name
- QUADRIH (NCT01725542)
- Testing
- Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a
- Where
- France
- Volunteers
- 75 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
Immunogenicity is reduced in immunocompromised patients. The aim of this prospective randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of anti-HAV vaccine in HIV-1 infected patients with CD4…
- Trial name
- HEPAVAC (NCT00190242)
- Testing
- group1, group2
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Human Immunodeficiency Virus, Hepatitis C, Chronic
HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
This is an prospective open label pilot study conducted over 32 weeks. A total of 25 eligible participants who are infected with HCV and HIV will be recruited from 2 Canadian HIV Trials Network (CTN) sites (Ottawa Hospital…
- Trial name
- CTN289 (NCT02660905)
- Testing
- E/C/F/TAF;, Ledipasvir-Sofosbuvir
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Ottawa Hospital Research Institute
HIV Infections, Liver Toxicity
Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
The purpose of this study is to demonstrate the difference in frequency and level of liver function disturbance between patients on efavirenz based ART, and patients on nevirapine based ART in HBV and HCV co-infected patients…
- Conditions
- HIV Infections, Liver Toxicity, Hepatitis Co-infection
- Trial name
- NCT01273142
- Volunteers
- 100 people
- Sponsor
- Henan Provincial People's Hospital
HIV
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population.
- Trial name
- ViDyMoCo (NCT02836782)
- Testing
- Blood sample withdrawal
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Catholic University of the Sacred Heart
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1…
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- TURQUOISE-I (NCT01939197)
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 318 people
- Sponsor
- AbbVie
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Human Immunodeficiency Virus
Maraviroc Efficacy for Hepatitis C
This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus (HIV) and taking…
- Trial name
- MAVERIC (NCT02881762)
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Chronic Hepatitis C, Co-Infection HIV-HCV
Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV
The rapidly progression of the disease in HIV-HCV co-infected patients justify the treatment. Combination of Peg interferon and Ribavirin is the best treatment because it improve the compliance of treatment.
- Trial name
- NCT00611819
- Testing
- Peg interferon + Ribavirin
- Where
- 18 sites in Spain
- Volunteers
- 59 people
- Sponsor
- University of Valencia
Hepatitis C, HIV Infections
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV…
- Trial name
- NCT00983853
- Testing
- peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
HIV-1 and Hepatitis C Co-Infection
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Insulin resistance is common in people coinfected with HIV and Hepatitis C virus (HCV) and is associated with poor responses to treatment for HCV. Pioglitazone is an FDA-approved medication for the treatment of type 2 diabetes.
- Trial name
- NCT00665353
- Testing
- pioglitazone, peginterferon, ribavirin
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection, Hepatitis C, Chronic
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current…
- Conditions
- HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence
- Trial name
- NCT03549312
- Testing
- Genvoya, Epclusa, Biktarvy
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
Hepatitis C, HIV Infections
Leukapheresis for Research on HCV-Coinfected Patients
This study will collect quantities of white blood cells from patients infected with the hepatitis C virus (HCV) for research on the interactions between HCV and the human immunodeficiency virus (HIV) in people infected with both…
- Trial name
- NCT00076427
- Where
- 4 sites in United States
- Volunteers
- 327 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis C
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)
The purpose of this study is to assess the efficacy and safety of grazoprevir (MK-5172) 100 mg in combination with elbasvir (MK-8742) 50 mg in the treatment of chronic hepatitis C virus (HCV) in participants who are co-infected…
- Trial name
- NCT02105662
- Testing
- Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
- Volunteers
- 218 people
- Sponsor
- Merck Sharp & Dohme LLC